AMGEN INC insider buying and selling
7 Form 4 filings against AMGEN INC (AMGN) in the last 90 days. Below are the transactions from 4 recent filings, one per insider where the window allows, as filed.
| Date | Insider | Role | Transaction | Code | Shares | Price | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-08-13 | Khosla Rachna | SVP, Business Development | option exercise | M | 1,252 | $162.60 | 7,656 |
| 2026-08-13 | Khosla Rachna | SVP, Business Development | open-market sale | S | 1,252 | $416.43 | 6,404 |
| 2026-08-11 | Khosla Rachna | SVP, Business Development | open-market sale | S | 2,000 | $412.57 | 6,404 |
| 2026-08-07 | Busch Matthew C. | VP, Finance & CAO | grant/award | A | 730 | 5,080 | |
| 2026-08-07 | ISHRAK OMAR | director | grant/award | A | 85 | 7,486 | |
| 2026-08-07 | HOLLEY CHARLES M | director | grant/award | A | 103 | 12,990 |
What the filings show
Across the 4 filings read here, 4 insiders at AMGEN INC (AMGN) reported 2 open-market sales of 3,252 shares worth about $1.3M.
The largest by value was Khosla Rachna (SVP, Business Development), with about $1.3M sold on the open market.
7 Form 4 filings were made against AMGEN INC in the 90 days to October 9, 2026; the paid report reads all of them.
The Form 4 flow against AMGEN INC, parsed and explained
The free view above is the newest few filings. The paid report reads the newest Form 4 filings of the last 90 days (up to 100), separates open-market buys and sales from awards, exercises and tax withholding, totals the flow per insider, flags 10b5-1 plans where the filing notes them, and hands you a cited write-up plus a downloadable transactions table.
Generated from public SEC EDGAR filings. Filing data is shown as filed. This is information, not investment advice.